We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

RICHMOND, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic ...

RICHMOND, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases ...

On Monday, BioAge Labs Inc (NASDAQ:BIOA) stock received a positive outlook from a major financial institution, as coverage was initiated with a Buy rating and a price target set at $42. The ...

On Monday, Morgan Stanley (NYSE:MS) initiated coverage on BioAge Labs Inc (NASDAQ:BIOA), assigning the stock an Overweight rating and setting a price target of $40.00. The new rating reflects the ...

Goldman Sachs initiated coverage of BioAge Labs (BIOA) with a Not Rated. The firm models for peak azelaprag sales of $8.5B in 2036 via peak penetration of 15% into the incretin-treated market.

Na segunda-feira, as ações da BioAge Labs Inc (NASDAQ:BIOA) receberam uma perspectiva positiva de uma importante instituição financeira, com o início da cobertura com recomendação de Compra e um preço ...

BioAge Labs, Inc. (BIOA) has received a new Buy rating, initiated by Morgan Stanley analyst, Jeffrey Hung. Jeffrey Hung’s rating is based on several promising developments at BioAge Labs, Inc ...